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Background: Non-infectious uveitis can cause chronic relapsing and remitting ocular 
inflammation, which may require high dose systemic immunosuppression to prevent 
severe sight loss. It has been classically described as an autoimmune disease, mediated 
by pro-inflammatory Th1 and Th17 T-cell subsets. Studies suggest that natural immu-
nosuppressive CD4+CD25+FoxP3+ T-regulatory cells (Tregs) are involved in resolution of 
inflammation and may be involved in the maintenance of clinical remission.
Objective: To investigate whether there is a peripheral blood immunoregulatory phe-
notype associated with clinical remission of sight-threatening non-infectious uveitis 
by comparing peripheral blood levels of Treg, Th1, and Th17, and associated DNA 
methylation and cytokine levels in patients with active uveitic disease, control subjects 
and patients (with previously active disease) in clinical remission induced by immunosup-
pressive drugs.
Methods: Isolated peripheral blood mononuclear cells (PBMC) from peripheral blood 
samples from prospectively recruited subjects were analyzed by flow cytometry for CD3, 
CD4, FoxP3, TIGIT, T-bet, and related orphan receptor γt. Epigenetic DNA methylation 
levels of FOXP3 Treg-specific demethylated region (TSDR), FOXP3 promoter, TBX21, 
RORC2, and TIGIT loci were determined in cryopreserved PBMC using a next- generation 
sequencing approach. Related cytokines were measured in blood sera. Functional sup-
pressive capacity of Treg was assessed using T-cell proliferation assays.
results: Fifty patients with uveitis (intermediate, posterior, and panuveitis) and 10 con-
trol subjects were recruited. The frequency of CD4+CD25+FoxP3+ Treg, TIGIT+ Treg, and 
T-bet+ Treg and the ratio of Treg to Th1 were significantly higher in remission patients 
compared with patients with active uveitic disease; and TIGIT+ Tregs were a significant 
predictor of clinical remission. Treg from patients in clinical remission demonstrated a 
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inTrODUcTiOn
Uveitis, defined as inflammation of the uveal inner layer of the 
eye, is the fifth commonest cause of visual loss in the devel-
oped world, accounting for about 10–15% of the cases of total 
blindness (World Health Authority definition) and up to 20% 
of legal blindness (1). Incidences vary between 38 and 200 per 
100,000 (2). Uveitis can affect people of all ages but occurs most 
frequently in the working age population (20–50  years), with 
35% affected remaining visually disabled (3). In the majority of 
cases, the inflammation in uveitis is non-infectious, of idiopathic 
and presumed autoimmune etiology. This type of disease may 
follow a relapsing, remitting course, which is clinically chal-
lenging to manage. Severe cases may require treatment with 
high dose oral corticosteroid drugs to minimize irreversible 
damage to the retina and visually important structures, which 
result in sight loss. Uveitis is a clinically heterogenous disease: at 
least 150 disorders are known to be associated with intraocular 
inflammation, although these disorders are individually rare. The 
Standardization of Uveitis Nomenclature (SUN) working group, 
therefore, developed clinical criteria to classify uveitis based on 
the anatomical localization of the inflammation (4). These criteria 
are useful but they do not define specific disease entities, phases 
of disease or include immunological biomarkers.
Our understanding of the immune mechanisms involved 
in non-infectious uveitis has derived from animal studies of 
experimental autoimmune uveitis (EAU) (5). Inflammation in 
EAU is mediated by Th1 and Th17 subsets of self-reactive CD4 
T-lymphocytes. The Th1 and Th17 lineages are characterized by 
expression of T-bet (Tbx21) and retinoic-acid related orphan 
receptor (ROR) γ-t (Rorc) transcription factors and secretion 
of the “signature” pro-inflammatory cytokines IFNγ and IL-17, 
respectively. Phenotypically categorized CD4+CD25+FoxP3+ 
T-regulatory cells (Tregs) exist as a naturally occurring mecha-
nism to suppress these autoreactive T-cells through production 
of anti-inflammatory cytokines such as IL-10 and transform-
ing growth factor β (TGF-β) (6), in addition to many other 
mechanisms. Studies in rat models of EAU have shown that 
during resolution of the first acute attack of uveitis, the number of 
 ocular Treg is increased (7). In those rats that went on to develop 
recurrent EAU, the suppressor function of Treg was found to be 
weaker (7). In murine models of EAU, a significantly increased 
frequency and immunoregulatory action of CD4+CD25+ Treg 
cells has been associated with the regression of EAU, suggesting 
that CD4+CD25+ Tregs are induced during EAU and may be 
involved in disease resolution (8). Further evidence in the mouse 
model demonstrates that retina-specific functionally suppressive 
FoxP3+ Tregs accumulate in inflamed eyes and persist for several 
months after disease remission (9). Depletion of Treg at the peak 
of uveitis delayed resolution and, following resolution where 
mice displayed a low grade chronic inflammation, Treg depletion 
precipitated disease relapse (9).
Many human studies have examined the role of Treg in systemic 
autoimmune diseases, where defects in Treg numbers and/or 
suppressive function have been found, in addition to imbalances 
between pro-inflammatory T-effectors and immunosuppressive 
Treg (10, 11). Patients with active uveitis have decreased periph-
eral blood levels of Tregs compared with healthy control subjects, 
with levels being significantly upregulated during disease remis-
sion (12, 13). Low or absent levels of FoxP3 mRNA are found in 
Tregs from patients with severe, recalcitrant uveitis (13). In rheu-
matoid arthritis (RA), Tregs recover their suppressive function 
after immunomodulating treatment with anti-tumor necrosis 
factor (TNF) α (11) monoclonal antibody (Ab) therapy. More 
specifically, the anti-TNFα agent, adalimumab, has been shown 
to restore immune tolerance in RA through expansion of func-
tional Foxp3+ Treg cells, equipped to suppress Th17 effector cells 
(11, 14, 15). In clinical trials of systemically administered immu-
nomodulating therapies in uveitis, induction of disease remission 
is associated with systemic upregulation of Tregs and modulation 
of cytokine production (16, 17). However, pharmacological effects 
on cytokines have also been demonstrated without a significant 
increase in the proportion of systemic FoxP3+ Treg levels (18). 
Taken as a whole, these studies suggest that the mechanism of 
disease remission in uveitis may involve upregulation of systemic 
Treg and/or restoration of their suppressive function, the effects 
high level of in vitro suppressive function compared with Treg from control subjects and 
from patients with untreated active disease. PBMC from patients in clinical remission had 
significantly lower methylation levels at the FOXP3 TSDR, FOXP3 promoter, and TIGIT 
loci and higher levels at RORC loci than those with active disease. Clinical remission 
was also associated with significantly higher serum levels of transforming growth factor 
β and IL-10, which positively correlated with Treg levels, and lower serum levels of IFNγ, 
IL-17A, and IL-22 compared with patients with active disease.
conclusion: Clinical remission of sight-threatening non-infectious uveitis has an immu-
noregulatory phenotype characterized by upregulation of peripheral Treg, polarized 
toward T-bet and TIGIT. These findings may assist with individualized therapy of uveitis, 
by informing whether drug therapy has induced phenotypically stable Treg associated 
with long-term clinical remission.
Keywords: uveitis, T-regulatory cells, TigiT, T-bet, ocular inflammation, remission, Th1, Th17
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of which may be mediated through cytokines. Furthermore, 
“functional” Treg seem to be important for preventing disease 
relapse and maintaining long-term clinical remission.
A lack of consensus regarding immunophenotypic markers 
for functionally suppressive Treg has meant that their status 
in human autoimmune disease has not been fully understood. 
Inflammatory environments induce T-cell plasticity (19) in which 
peripherally induced CD4+CD25+FoxP3+ Treg (pTregs) subsets 
may co-exist with more phenotypically stable thymically derived 
CD4+CD25+FoxP3+ Tregs (nTregs). Foxp3 is considered the Treg 
“master transcription factor” because it is critically required 
for Treg-cell development and function and for suppressing 
autoimmunity (20–23). However, it is also known that activated 
human T-cells may transiently upregulate FOXP3 and that these 
FoxP3+ T-cells are not effective at suppressing inflammation 
(24–27). Studies have revealed that a specific DNA hypometh-
ylation pattern, the Treg-specific demethylated region (TSDR), 
a hypomethylated region within the FOXP3 gene, is associated 
with enhancement and stabilization of Foxp3 expression in Treg 
(28–31). In combination with CD25 and FoxP3 expression, the 
TSDR has allowed identification of Treg with a stable phenotype 
(32). The addition of a methyl group (–CH3) to DNA is a com-
mon epigenetic mechanism that cells use to switch genes “off.” 
Extensive methylation of cytosine in DNA is known to correlate 
with reduced gene transcription. DNA methylation is generally 
thought to play an essential role in T-cell function and failure to 
maintain DNA methylation patterns in mature T-cells has been 
implicated in the development of autoimmune disease (33).
A recently discovered co-inhibitory molecule, T cell immuno-
receptor with Ig and ITIM domains (TIGIT), is expressed by Treg 
(34) and suppresses a range of immune cells. Studies show that 
TIGIT ligation directly inhibits T cell proliferation and cytokine 
production in CD4+ T cells (35). Furthermore, increased expres-
sion of TIGIT, which delineates Treg from activated effector 
T cells, has been associated with hypomethylation and FOXP3 
binding at the TIGIT locus (36). Treg cells expressing TIGIT were 
found to selectively inhibit Th1 and Th17, but not Th2 responses 
(37). Since it is known that the Th1 and Th17 subsets are pivotal 
to the pathogenesis of autoimmune disease, TIGIT may be a bio-
marker of stable, functionally suppressive Treg in these diseases.
Treatment paradigms of systemic autoimmune diseases, such 
as RA and inflammatory bowel disease, have now evolved beyond 
partial symptom control (38). The goal of inducing and maintain-
ing sustained biological remission, to improve long-term disease 
outcomes, has been described as a “treat-to-target” strategy (38). 
A working definition of sustained “deep remission,” which includes 
long-term biological remission and symptom control with defined 
patient outcomes, including no disease progression, has been pro-
posed for Crohn’s disease (38, 39). “Clinical remission” in uveitis, 
however, has not been defined or investigated as an immunologi-
cally distinct phase of disease. Understanding the immunological 
mechanisms underlying disease remission, in addition to the focus 
on inhibiting inflammation, could have significant implications for 
clinical phenotyping of uveitis and determining the best therapeu-
tic approach to induce remission for each patient.
In this study, we investigate the hypothesis that there is a 
peripheral blood immunoregulatory T-cell phenotype associated 
with sustained clinical remission, using a prospective study 
design with recruitment of 50 non-infectious uveitis patients 
(without identifiable systemic disease) and 10 control subjects. 
Clinical remission is defined as a 6-month period of remission 
without treatment, in patients with previously active relapsing 
and remitting disease, which clinically responded to systemic 
immunosuppressive therapy. We evaluate the frequency of 
CD4+CD25+FoxP3+ Treg and, additionally, the frequency of 
TIGIT+ Treg, which we propose to be a biomarker of functionally 
suppressive Treg. Co-expression of FoxP3, ROR γ-t, and T-bet, 
the ratio of Treg to putative T-effectors, and serum levels of 
cytokines associated with these T-cell subsets are also analyzed. 
Furthermore, we evaluate whether there is an epigenetic immune 
methylation pattern associated with clinical remission in uveitis, 
using a targeted next-generation sequencing (NGS) bisulfate 
sequencing approach toward T-cell genes of interest.
MaTerials anD MeThODs
Patient recruitment and specimen 
collection
A total of 50 patients with a diagnosis of idiopathic non-
infectious uveitis were consecutively recruited to the study from 
Moorfields Eye Hospital, London, UK between November 2014 
and December 2016. Inclusion criteria for all patients were 
as follows: age 18–59  years; a current or previous diagnosis of 
non-infectious intermediate, posterior or panuveitis as per SUN 
(4); and the absence of known associated infectious disease or 
systemic inflammatory disease. Eligibility for recruitment was 
further determined by uveitic disease activity. To meet the clinical 
criteria for disease “in clinical remission,” patients were required 
to have no signs of disease activity at the time of recruitment; 
have a previous diagnosis of active non-infectious chronic 
relapsing and remitting uveitis which was treated with oral 
corticosteroids ±  second-line corticosteroid-sparing treatments 
before the period of clinical remission; and have discontinued 
all immunosuppressive treatment and remained “quiescent” 
(without reactivation of disease) for at least 6 months. To meet 
the criteria for “active” disease, patients were required to have 
new onset of uveitic disease occurrence at the time of recruitment 
(a new diagnosis or reactivation of existing disease), which was 
regardless of treatment status. Disease activity was determined 
by clinical symptoms, examination with slit lamp biomicroscopy 
and clinical imaging (optical coherence tomography, fundus 
autofluorescence, and fluorescein angiography). Patients who met 
the study inclusion criteria and who were clinically assessed to 
have active disease (i.e., anterior chamber cells ≥0.5+, vitreous 
cells ≥0.5+, inflammatory cystoid macular edema, optic disk 
edema, active vasculitis, or new/active chorio-retinal lesions) 
were considered eligible as “active” patients in the study. As con-
trols, 10 age-matched subjects with no history of uveitis, systemic 
inflammatory disease or known infectious disease were enrolled 
onto the study.
A 30 mL sample of heparinized peripheral venous blood was 
obtained from all subjects. In the active cohort, samples were 
obtained before starting/modifying the immunosuppressive 
4Gilbert et al. Treg in Clinical Remission of Uveitis
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 907
treatment regime. Additional peripheral venous blood samples 
were prospectively obtained from four active patients at 2, 6, and 
12 months after starting/changing treatment.
This study was carried out in accordance with the recommen-
dations of the UK National Research Ethics Service—London 
Harrow Committee and the Moorfields Eye Hospital National 
Health Service Foundation Trust, Department of Research and 
Development (13/LO/1653; 16039). All subjects gave written 
informed consent in accordance with the Declaration of Helsinki.
Peripheral Blood Mononuclear cells 
(PBMc) isolation, cell culture, and 
cryopreservation
Peripheral blood mononuclear cells were obtained from fresh 
heparinized blood (≤4 h following venupuncture) by Histopaque 
density gradient centrifugation (Histopaque-1077, Sigma-
Aldrich, Gillingham, UK) and washed twice with RPMI 1640 
with 10% human AB Serum (Sigma-Aldrich). 10 ×  106 PBMC 
from each sample were stained for multi-color flow cytometry.
For experimental cell culture conditions requiring stimu-
lated cells, freshly isolated PBMC were cultured in X-VIVO 15 
medium with l-glutamine, gentamicin, and phenol red (Lonza, 
Cambridge, UK) for 5 days, with the addition of 5 µg/mL soluble 
anti-CD3 (HIT3a) NA/LE, 1  µg/mL anti-CD28 NA/LE (BD 
Biosciences), and 50  IU IL-2 IS/mL (Miltenyi Biotec, Woking, 
UK) to the culture media, unless otherwise specified.
The remaining PBMC were cryopreserved in human AB serum 
with 10% Hybri-Max Sterile-filtered DMSO (Sigma-Aldrich) at 
−20°C for 1 h before transfer to −70°C and then to liquid nitro-
gen for longer term storage, for subsequent DNA isolation and 
methylation analysis.
antibodies
For multi-color immunophenotyping by flow cytometry, the 
following Abs were used: RORγt-Alexa Fluor 488, T-bet-
PerCP-Cy5.5, CD3-Vioblue, CD25-Brilliant Violet 711, CD4-
Brilliant Ultraviolet 395, FoxP3-Alexa Fluor 647, TIGIT-PE, 
and Near Infrared live/dead fixable cell stain. For intracellular 
cytokine staining by flow cytometry, the following Abs were used: 
CD3-Vioblue, CD4-Brilliant Ultraviolet 395, IL-10-PE-CF594, 
IFNγ-BV605, IL-17A PE-Vio-770, and Near Infrared live/dead 
fixable cell stain. For live cell sorting, the following Abs were used: 
CD4-PerCP-Cy5.5, CD127-Brilliant Violet 605, CD3-Brilliant 
Violet 785, CD25-PE-Dazzle 594, CD14-APC-Fire, and SYTOX 
blue dead cell stain. Abs were provided by BioLegend (London, 
UK), BD Biosciences (Oxford, UK), eBiosciences (Hatfield, UK), 
Miltenyi Biotec, and ThermoFisher Scientific (Dartford, UK).
Treg and Th1/Th17 immunophenotyping 
by Flow cytometry
The peripheral blood levels of the following cell subsets were 
determined by flow cytometry: CD25+FoxP3+ Treg, CD25+FoxP3+ 
TIGIT+ Treg, T-bet+ Th1, RORγt+ Th17, T-bet+RORγt+ Th1/17, 
Foxp3+T-bet+ Treg, and Foxp3+RORγt+ Treg in the CD3+CD4+ 
subset. Single-cell suspensions were washed in PBS (Sigma-
Aldrich) and stained with directly conjugated Abs for cell surface 
molecules (CD3, CD4, CD25, TIGIT), then stained with Zombie 
NIR (BioLegend) fixable dead cell stain, then fixed and permea-
bilized with a transcription factor fixation/permeabilization kit 
(eBiosciences), and subsequently stained using directed conju-
gated Abs recognizing transcription factors (FoxP3, RORγt, and 
T-bet). Subject-specific fluorescence-minus-one (FMO) controls 
for CD25, TIGIT, FoxP3, RORγt, and T-bet were included in each 
experiment.
Flow cytometric data were acquired using an LSRFortessa 
(BD Biosciences, San Jose, CA, USA) and BD FACSDiva version 
6.1.3 software with a total of 50,000 events being recorded for 
each sample through a live, single-cell CD3+CD4+ gate (gating 
strategy shown in Figure 1). Viable cells were identified by low 
uptake of the fixable dead cell stain. Single-stained OneComp 
and UltraComp beads (eBiosciences) were used to generate 
compensation matrices. FMO controls were used to identify gat-
ing boundaries where cell populations were ill-defined. Analysis 
of flow cytometry data was performed using FlowJo version 10 
software (TreeStar Inc., Ashland, OR, USA).
cytokine analysis
Whole blood samples were centrifuged following collection to 
obtain serum supernatant samples, which were stored in 1.5 mL 
aliquots at −70°C for subsequent multiplex cytokine analysis. 
Cryopreserved subject serum cytokine samples were thawed 
and immediately analyzed for cytokines IL-10, IFNγ, IL-17A, 
and IL-22 by multiplex bead arrays (R&D Systems) using a 
MAGPIX Luminex system (Luminex, TX, USA). The data 
were analyzed using xPONENT software (Luminex). Acidified 
serum aliquots from the same subject samples were analyzed for 
TGF-β by ELISA (R&D Systems) using the optical density set-
ting of the Modulus II Microplate Multimode Reader (Promega 
Corporation). Minimum levels of detection based on standard 
curves for each array were as follows: IL-10 (7.30 pg/mL), IFNγ 
(17.30 pg/mL), IL-17A (2.65 pg/mL), IL-22 (6.10 pg/mL), and 
TGF-β (7.4 pg/mL).
For intracellular cytokine staining, freshly isolated PBMC from 
a patient with active disease (Patient 1) at 2 and 6 months after 
baseline were stimulated with Dynabeads Human T-Activator 
CD3/CD28 (ThermoFisher Scientific) for 24 h or a cell stimula-
tion cocktail (containing PMA and ionomycin) 1:500 for 6 h as a 
positive control, with the addition of protein transport inhibitor 
(containing Brefeldin A) to the culture medium for the last 4 h. 
Staining and flow cytometric analyses were as described earlier, 
with the following modifications: directly conjugated Abs for cell 
surface molecules (CD3 and CD4); fixation and permeabilization 
with an intracellular cytokine fixation/permeabilization kit (BD 
Biosciences); and directly conjugated Abs recognizing intracel-
lular cytokines (IL-10, IFNγ, and IL-17A). Subject-specific FMO 
controls for IL-10, IFNγ, and IL-17A were included in each 
experiment.
cell sorting and T-cell Proliferation assay
Freshly isolated PBMCs from subject samples in each group 
were stained with CD3, CD4, CD25, CD127, and CD14 cell 
surface Abs. CD3+CD4+CD25+CD127lo, CD3+CD4+CD25−, and 
CD14+ populations representing Treg, putative T-effectors, and 
FigUre 1 | Flow cytometry gating strategy. Flow cytometric data were acquired using an LSRFortessa (BD Biosciences, San Jose, CA, USA) and BD FACSDiva 
version 6.1.3 software with a total of 50,000 events being recorded for each sample through a live, single-cell CD3+CD4+ gate. Viable cells were identified by low 
uptake of the fixable dead cell stain. Single-stained OneComp and UltraComp beads (eBiosciences) were used to generate compensation matrices. Fluorescence-
minus-one controls were used to identify gating boundaries where cell populations were ill defined.
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monocyte (MC) subsets, respectively, were isolated directly from 
the stained PBMC by means of high speed Influx flow cytometric 
cell sorting (BD Biosciences, San Jose, CA, USA) (gating strategy 
shown in Figure 2A).
CD3+CD4+CD25− T-cells were washed and resuspended at 
10 × 106/mL in sterile PBS (Sigma-Aldrich) containing 1 µL of 
1  mM violet proliferation dye (VPD) 450 stock solution (BD 
Biosciences) for each 1 mL of cell suspension for a final VPD450 
concentration of 1 µM, according to the manufacturer’s instruc-
tions (Figure 2B). The cells were stained by incubating the dye-
cell suspension in a 37°C water bath for 10  min. The reaction 
was quenched by adding 9× the original volume of PBS to the 
cells, followed by centrifugation, discarding the supernatant, and 
resuspending the cells in 10 mL of RPMI 1640 medium with 10% 
FBS before washing again.
The in vitro capacity of the Treg to suppress the proliferation 
of VPD450-labeled CD3+CD4+CD25− responding T-cells (Tresp) 
was assessed in 96-well plates (1 ×  106 per well density) in a 
classical 5-day coculture assay, as follows: VPD450-labeled 
CD3+CD4+CD25− Tresp were cocultured with sorted CD14+ 
MCs at 1:1 ratio and sorted CD3+CD4+CD25+CD127lo Tregs 
were cocultured with Tresp and MC at a 1:3:3 ratio. Cell culture 
conditions were as previously described. Data were acquired by 
flow cytometry and analyzed using the cell tracking function of 
Modfit LT modeling software (Verity Software House, ME, USA) 
to generate a statistic termed proliferation index (PI) (Figure 2C). 
Percentage (%) suppression was determined for each subject 
sample as follows, adapted from previously described methods 
for conducting suppression assays from small numbers of isolated 
T-cells (15, 40):
 
% ( ) ( )
( )
. suppression Tresp MC Tresp MC Treg
Tresp MC
=
+ + +
+
×
− 100
 
Dna isolation and Methylation analysis
Genomic DNA extraction was performed directly on samples 
of thawed cryopreserved PBMC from each subject group using 
the DNeasy Blood and Tissue Kit (Qiagen, Manchester, UK). The 
samples were then analyzed at five DNA sites of cytosine (CpG) 
methylation (FOXP3 TSDR, FOXP3 promoter, TBX21, RORC2, 
and TIGIT) with bisulfite Amplicon Sequencing using an NGS 
approach on the Illumina sequencing platform (Fluidigm, CA, 
USA) (Figure  3; bisulfite Amplicon target sites are shown in 
Figure S1 in Supplementary Material).
FigUre 3 | Overview of targeted DNA methylation analysis methods. 
Summary work-flow of bisulfite Amplicon Sequencing using a next-
generation sequencing approach with the Illumina sequencing platform 
(Fluidigm, CA, USA).
FigUre 2 | Cell sorting and T-regulatory cell (Treg) suppression assays. (a) Cell sorting strategy to isolate Treg (CD4+CD25+CD127lo) and T-effectors (CD4+CD25−)  
in CD3+ T-cell subset. (B) Post-cell sort staining of T-effectors with violet proliferation dye (VPD) 450 cell tracking dye. (c) Modfit modeling of in vitro T-cell 
proliferation index using VPD 450. (D) Comparison of % suppression of T-cell proliferation by Treg isolated from the different subject groups.
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Before DNA bisulfite treatment, the integrity of the DNA 
was assessed using the Agilent 2100 Bioanalyser Tapestation 
(Agilent Technologies, Waldbronn, Germany), and the DNA 
concentration was measured using Qubit Fluorometric Quanti-
fication (ThermoFisher Scientific). 500  ng of normalized DNA 
was bisulfite converted using the EZ DNA Methylation kit 
(Cambridge BioSciences, Cambridge). The incubation conditions 
recommended by the manufacturers guide [95°C for 30 s, 50°C 
for 60 min] × 16 cycles, 4°C hold were used for the conversion 
reaction. The yield of bisulfite converted DNA was estimated using 
the RNA-40 setting on the NanoDrop 8000 Spectrophotometer 
V2.0 (ThermoScientific, USA). Primers for the target sites were 
designed using Pyromark Assay Design 2.0 software (Qiagen) 
and synthesized with Fluidigm Universal CS1 and CS2 tags 
(Fluidigm, San Francisco, USA) to allow for the construction of 
DNA libraries using Fluidigm proprietary indexes (see Table S2 in 
Supplementary Material for primer sequences Fluidigm CS1 and 
CS2 tags are highlighted in bold). MyTaq™ HS DNA Polymerase 
(Bioline, USA) was used to optimize the assays and amplify the 
DNAs. The PCR products were checked for amplification on 
an Agilent 2100 Bioanalyser D1K Tape (Agilent Technologies, 
Waldbronn, Germany) after which unique Fluidigm Barcodes 
(Table S3 in Supplementary Material) were added to the PCR 
product under the following PCR cycling conditions: 95°C for 
10 min (95°C for 15 s, 60°C for 30 s, and 72°C for 1 min) cycle 14 
times; 4°C hold. To check that the barcodes had been successfully 
incorporated onto the PCR products, the barcoded PCR product 
was run on an Agilent D1K tape. If the barcodes had attached, 
then a shift of ~60 bp was observed between the PCR product and 
the barcoded products. Equal volumes of barcoded products were 
pooled and primer dimer was removed using Agencourt Ampure 
XP beads (Beckman Coulter Life Sciences) at a volume of 1:1. 
The pool was quantified using High Sensitivity Qubit Reagents 
(Qiagen), and the library size was measured using the Agilent 
2100 High Sensitivity D1K (Agilent Technologies, Waldbronn, 
Germany) to calculate the molarity of the library before sequenc-
ing. 150-bp Paired-end sequencing was performed using the 
TaBle 2 | Subject immunosuppressive treatment characteristics.
control 
(n = 10)
active  
(n = 13)
Quiescent 
(n = 37)
On oral immunosuppressive  
treatment at baseline, no. (%)
– 6 (46) 0 (0)
Previous oral immunosuppression  
received, no. (%)
10 (77) 37 (100)
Prednisolone only 4 (40) 22 (59)
Additional second-line  
immunosuppression
6 (60) 15 (41)
Mycophenolate mofetil – 3 (23) 5 (14)
Ciclosporin – 0 (0) 7 (20)
Azathioprine – 1 (8) 2 (5)
Methotrexate – 0 (0) 1 (3)
Biologicals – 0 (0) 1 (3)
Median duration of previous oral 
immunosuppression, months (IQR)
– 6 (4–12) 24 (7–72)
Median values are in bold font.
TaBle 1 | Subject demographics and clinical characteristics.
characteristics control  
(n = 10)
active  
(n = 13)
Quiescent  
(n = 37)
Median age in years (IQR) 30 (29–33) 41 (27–46) 47 (35–55)
Female sex—no. (%) 6 (60) 6 (46) 19 (51)
race or ethnic group, no. (%)
White/European 6 (60) 6 (46) 26 (70)
Asian/Middle Eastern 4 (40) 3 (23) 10 (27)
Black/Afro-Carribean 0 4 (31) 1 (3)
Uveitis sUn classification
Intermediate – 6 (46) 16 (43)
Posterior – 1 (8) 6 (16)
Panuveitis – 6 (46) 15 (41)
Bilateral disease, no. (%) – 10 (77) 30 (81)
Median visual acuity (log MAR) – 0.2 (0.1–0.4) 0.2 (0.1–0.5)
Visually significant cataract (%) – 2 (15) 9 (24)
Previous cataract surgery – 2 (15) 15 (41)
Median disease duration since 
diagnosis, months (IQR)
– 33 (7–119) 147 (50–249)
Median values are in bold font.
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Miseq Illumina sequencer (Illumina, Inc.) to a total of 400,000 
reads passing filter per sample. Bismark (41) was used to align 
bisulfite-treated reads to a human reference genome and calculate 
the cytosine methylation calls at the target sites. Biostatistical 
analysis generated beta (%) methylation values as a ratio of 
methylated to unmethylated DNA for each CpG site of interest.
statistical analysis
Statistical analysis of final datasets was performed with SPSS ver-
sion 24 (IBM Software) and GraphPad Prism version 7 (GraphPad 
Software). Differences between groups were determined by the 
Kruskal–Wallis test with post hoc Bonferroni correction for mul-
tiple comparisons. Bivariate correlations between immunological 
variables were calculated using Spearman’s test. Relationships 
between selected variables, which had clinically relevant associa-
tions, were modeled using multiple linear regression and logistic 
regression, using “stepwise” or “enter” variable entry, respectively. 
Where possible, variables with a non-normal distribution were 
transformed to a normal distribution, using a log transformation, 
to include in the multiple regression model. All significance tests 
were two-tailed. P-values  <  0.05 were considered significant. 
Results are expressed as frequency n (%) or median (IQR), unless 
otherwise stated.
resUlTs
subject characteristics
A total of 50 uveitis patients and 10 control subjects were 
recruited to the study (Table 1). Of the 50 patients recruited, 
37 were in clinical remission and 13 had active disease at the 
time of recruitment. 22 (59%) of the patients in the clinical 
remission group received previous therapy with corticosteroids 
only, the remaining patients received additional second-line 
oral immunosuppressive treatment (Table  2). Of the active 
patients, who all had intermediate uveitis, posterior uveitis 
or panuveitis, 11 (85%) had cells and/or haze in the vitreous, 
7 (54%) had cells in anterior chamber, 6 (46%) had macular 
edema, 3 (23%) had optic disk edema, two (15%) had vasculitis, 
and 1 (8%) had chorio-retinal lesions at baseline. Six (46%) of 
these patients with active disease were on systemic immuno-
suppression at the time of recruitment. A subgroup analysis 
comparing the active patients on therapy and active patients 
not on therapy at baseline did not reveal any differences 
between the groups. Four of the 13 active patients underwent 
additional immunophenotyping at 2, 6, and 12 months after 
starting or changing treatment. The immunological marker 
levels and comparison across the three subject groups (active, 
remission, and controls) with summary P-values are shown in 
Table 3 and Figure 4, with the post hoc pairwise comparisons 
and adjusted P-values shown in Table S1 in Supplementary 
Material.
clinical remission of Uveitis is associated 
With higher levels of Treg Polarized 
Toward T-bet and TigiT compared 
With active Disease
To determine whether there was a difference in peripheral blood 
Treg levels between control, active and quiescent subjects in dis-
ease remission, their PBMC were analyzed by flow cytometry for 
levels of CD25+FoxP3+ Treg, FoxP3+TIGIT+ Treg, FoxP3−TIGIT+ 
T-cells, and FoxP3+T-bet+ Treg in the CD3+CD4+ lymphocyte 
subset (Figure 5). Highly statistically significant differences were 
found between the active and remission groups in the levels of 
Treg (4.4 ± 1.2 vs 7.1 ± 1.3, P = 0.000), TIGIT+ Treg (2.5 ± 1.3 
vs 5.0 ± 0.9, P = 0.000) and T-bet+ Treg (0.7 ± 0.4 vs 1.1 ± 0.3, 
P = 0.000) (Figure 4). CD25+FoxP3+ Treg, FoxP3+TIGIT+ Treg, 
and FoxP3+T-bet+ Treg were also observed to increase as disease 
resolved in patients with active uveitis (Figure 6). The ratio of 
CD4+CD25+FoxP3+TIGIT+ Treg to CD4+FOXP3−TIGIT+ T-cells 
was significantly higher in the remission group compared with 
the active group (0.7 ± 0.2 vs 0.3 ± 0.2, P = 0.003). T-bet+FoxP3+ 
cell levels positively correlated with TIGIT+FoxP3+ cell levels 
across the three subject groups (r =  0.431, P =  0.001). There 
TaBle 3 | Comparison of immunological markers across the three subject groups.
immunological marker subject cohort 3-Way comparison
control active remission summary p-value
T-cell subsets (%) and ratios
CD25+FoxP3+ T-regulatory cell (Treg) 5.6 (5.3–6.7) 4.4 (3.6–6.0) 7.1 (5.8–8.3) 0.000***
CD25+TIGIT+FoxP3+ Treg 4.2 (3.3–4.4) 2.5 (2.1–4.3) 5.0 (4.2–5.9) 0.000***
TIGIT+FoxP3+:TIGIT+FoxP3− 0.6 (0.5–0.7) 0.4 (0.2–0.6) 0.6 (0.5–0.8) 0.049*
TIGIT+FoxP3+CD25+:TIGIT+FoxP3− 0.5 (0.4–0.6) 0.3 (0.1–0.4) 0.7 (0.5–0.9) 0.003**
Th1 (T-bet+) 57.1 (40.8–66.4) 58.6 (48.8–72.2) 48.5 (42.7–55.9) 0.025*
Th17 (RORγt+) 2.4 (1.2–4.5) 1.5 (0.8–4.4) 1.7 (1.2–3.2) 0.564
Treg:Th1 0.7 (0.6–0.8) 0.4 (0.3–0.6) 0.7 (0.5–0.9) 0.000***
Treg:Th17 0.4 (0.2–0.4) 2.0 (0.8–3.5) 2.8 (1.5–4.3) 0.001**
T-bet+FoxP3+ 0.7 (0.5–0.8) 0.7 (0.5–1.2) 1.1 (1.0–1.6) 0.000***
RORγt+FoxP3+ 0.6 (0.5–0.9) 0.5 (0.1–0.7) 0.6 (0.3–1.1) 0.363
RORγt+T-bet+ 1.5 (0.6–2.5) 1.0 (0.4–2.0) 1.5 (0.9–2.3) 0.183
serum cytokine levels (pg/ml)
IL-10 24.2 (22.8–25.4) 11.6 (9.8–11.8) 21.5 (20.0–22.8) 0.000***
Transforming growth factor β 56.9 (38.9–85.4) 62.7 (48.7–96.5) 161.1 (122.5–285.2) 0.001**
IFN-γ 208.4 (197.3–214.4) 408.8 (404.8–418.8) 297.8 (296.1–299.5) 0.000***
IL-17 13.9 (13.2–14.0) 14.8 (13.9–15.9) 13.0 (11.9–13.4) 0.003**
IL-22 19.9 (17.3–20.2) 20.6 (20.3–22.0) 18.3 (17.1–18.8) 0.002**
cpg site methylation levels (%)
FOXP3 promoter 69 (52–75) 72 (66–77) 53 (46–68) 0.037*
FOXP3 Treg-specific demethylated region 69 (61–71) 76 (68–83) 63 (59–67) 0.005**
TIGIT 54 (47–55) 59 (57–64) 48 (46–53) 0.004**
TBX21/T-BET 0.7 (0.6–0.8) 0.4 (0.3–0.5) 0.7 (0.5–0.8) 0.122
RORC2/RORγT 55 (52–61) 46 (44–51) 55 (51–58) 0.006*
Median values are in bold font.
*Significant at the 5% level.
**Significant at the 1% level.
***Significant at the 0.1% level.
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were no statistically significant differences between Treg levels in 
control and active uveitis patient groups.
FoxP3+rOrγt+ Tregs are not associated 
With clinical remission but May have 
a role in clinical resolution  
of non-infectious Uveitis
Peripheral blood levels were analyzed for CD3+CD4+FoxP3+ 
RORγt+ Treg (Figure  5). Although the remission and control 
groups had higher median levels of FoxP3+RORγt+ Treg com-
pared with the active group, these differences did not reach 
statistical significance (P  =  0.363) (Figure  4). However, an 
overall increase in FoxP3+RORγt+ Treg levels was observed over 
12  months in all four patients with active disease at baseline 
(Figure 6).
clinical remission of Uveitis is  
associated With Overall lower levels 
of Th1 Transcription Factors and a 
higher ratio of Treg to Th1 compared 
With active Disease
To determine whether there was a difference in Th1 (T-bet 
transcription factor expression) levels and ratios of Treg to 
Th1 between control, active and quiescent subjects in disease 
remission, their PBMC were analyzed by flow cytometry for 
levels of CD25+FoxP3+ Treg (Figure  5) and T-bet+ T-cells in 
the CD3+CD4+ lymphocyte subset. Significantly lower levels 
of T-bet transcription factor levels (48.5 ± 6.8 vs 58.6 ± 11.7, 
P = 0.024) and higher ratios of Treg:Th1 (0.7 ± 0.2 vs 0.4 ± 0.1, 
P =  0.001) were found in remission patients compared with 
active patients (Figure 4). Active patients also had significant 
lower ratios of Treg:Th1 compared with control subjects 
(0.4 ± 0.1 vs 0.7 ± 0.1, P = 0.013) (Figure 4). Disease resolution 
in active patients over the course of 12 months appeared to be 
associated with an increase in levels of Treg and decrease in 
levels of Th1 (Figure 6).
clinical remission of Uveitis is not 
associated With Overall lower levels 
of Th17 Transcription Factors or a higher 
ratio of Treg to Th17 compared 
With active Disease
To determine whether there was a difference in Th17 (RORγt+ 
transcription factor expression) levels and Treg:Th17 ratios 
between control, active and quiescent subjects in disease 
remission, their PBMC were analyzed by flow cytometry for 
levels of CD25+FoxP3+ Treg (Figure  5) and RORγt+ T-cells in 
FigUre 4 | Dot plots showing flow cytometry analysis results (% frequency or ratio) of peripheral blood levels of T-regulatory cell (Treg), Th1, and Th17 subtypes in 
CD3+CD4+ T-cell compartment, with comparisons across the three subject groups (active, remission, and controls). (a) % CD25+FoxP3+ Treg. (B) % FoxP3+TIGIT+ 
Treg. (c) Ratio of FoxP3+TIGIT+ Treg to TIGIT+FoxP3− T-cells. (D) % FoxP3+T-bet+ Treg. (e) % T-bet+ Th1. (F) Ratio of Treg to Th1. (g) % FoxP3+RORγt+ Treg.  
(h) % RORγt+ Th17. (i) Ratio of Treg to Th17. (J) % T-bet+RORγt+ “double positive” Th1/Th17.
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the CD3+CD4+ lymphocyte subset. No significant difference 
was found in Th17 levels between the three groups (P = 0.564), 
although it was noted that both active (2.0 ± 1.3) and remission 
(2.8 ± 1.4) patients had significantly higher Treg:Th17 ratios in 
comparison with control subjects (0.4 ± 0.3, P = 0.014; P = 0.000 
respectively) (Figure 4). Increased Th17 levels in three out of four 
patients with active disease were noted as the disease clinically 
resolved over 12 months (Figure 6).
FigUre 5 | Flow cytometry analysis plots showing representative examples of peripheral blood levels of T-regulatory cell (Treg) subtypes in the CD3+CD4+ T-cell 
compartment, across the three subject groups (active, remission, and controls). (a) % CD25+FoxP3+ Treg. (B) % TIGIT+ Treg in the (above) CD25+FoxP3+ Treg 
subset. (c) % FoxP3+TIGIT+ Treg (upper right quadrant) and TIGIT+FoxP3− T-cells (upper left quadrant). (D) % FoxP3+T-bet+ Treg (upper right quadrant).  
(e) % FoxP3+RORγt+ Treg (upper right quadrant).
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clinical remission of Uveitis is not 
associated With Decreased levels 
of “Double Positive” effector rOrγt+T-bet+ 
T-cells
Peripheral blood levels were analyzed for “double positive” 
RORγt+T-bet+ T-cells in the CD3+CD4+ subset. There was no 
significant difference in levels of RORγt+T-bet+ T-cells between 
the three groups (P = 0.183) (Figure 4).
clinical remission of Uveitis is associated 
With higher serum levels of TgF-β and 
il-10 and lower serum levels of iFnγ, 
il-17a, and il-22 compared With active 
Disease, and serum TgF-β and il-10 
levels Positively correlate With Treg levels
Cytokine levels of IL-10, TGF-β, IFNγ, IL-17A, and IL-22 were 
assayed in serum from 10 remission patients, 8 active patients 
and 5 control subjects from the above groups (Figures 7A–E). 
IL-10 levels were significantly higher in serum from remission 
patients compared with active patients (21.5 ± 2.4 vs 11.6 ± 1.5, 
P =  0.011), and lower in active patients compared with con-
trols (11.6 ± 1.5 vs 24.2 ± 2.3, P = 0.000). TGF-β levels were 
higher in remission patients than in active (161.1 ±  81.4 vs 
62.7 ± 24.0, P = 0.007) and control (161.1 ± 1.5 vs 56.9 ± 24.0, 
P = 0.004) subjects. Clinical remission was also associated with 
significantly lower serum levels of IFNγ (P =  0.015), IL-17A 
(P =  0.002), and IL-22 (P =  0.001) compared with patients 
with active disease. Increased intracellular IL-10 and IL-17A 
and decreased intracellular IFNγ levels were found in CD4+ 
T-cells from active uveitis, 6  months after starting treatment, 
when the disease had clinically resolved (Figure  7F). Serum 
TGF-β (r = 0.752, P <0.0001) and IL-10 (r = 0.667, P = 0.0005) 
levels positively correlated with Treg levels across all subjects 
(Figures 7G,H).
clinical remission of Uveitis is associated 
With Treg Which Demonstrate a high 
capacity to suppress Proliferating 
T-effectors
Cell-sorted populations of Treg, putative T-effectors and mac-
rophages were set up in in  vitro culture and the T-cell PI was 
modeled by Modfit software, which was used to calculate% 
suppression by Treg, as described earlier. Treg from active uveitis 
without treatment failed to suppress proliferation of T-cells in vitro 
(Figure 2D). By contrast, Treg from active uveitis treated with 
oral immunosuppression, Treg from control subjects and Treg 
from uveitis in clinical remission all showed in vitro functional 
suppression, with the highest suppressive capacity demonstrated 
by Treg from uveitis in clinical remission (Figure 2D). Data are 
shown from the following subjects: Patients 1 and 50 (in active 
disease group), Patient 49 (in clinical remission group), and 
FigUre 6 | T-regulatory cell (Treg), Th1 and Th17 % levels in patients with active disease at baseline, as disease resolved over 12 months of treatment with oral 
immunosuppression. (a) CD25+FoxP3+ Treg. (B) CD25+FoxP3+TIGIT+ Treg. (c) FoxP3+T-bet+ Treg. (D) FoxP3+RORγt+ Treg. (e) CD4+T-bet+ Th1. (F) CD4+RORγt+ Th17.
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Volunteer 2 (in control group). Patient 50 had active disease and 
had not yet started oral immunosuppression, whereas Patient 
1 had a diagnosis of active disease at baseline and had received 
6 months of oral immunosuppression.
lower levels of Methylation at Key 
epigenetic cpg sites Determining Treg 
Function in PBMc are associated With 
clinical remission but are not 
consistently Observed in clinical 
resolution of Uveitis
To determine whether there was a difference in methylation 
at epigenetic CpG sites associated with Treg function (FoxP3 
and TIGIT), bisulfite Amplicon Sequencing using an NGS 
approach was performed using cryopreserved PBMC from 
8 active patients, 8 control subjects and 12 remission patients. 
Cryopreserved served samples, at 12  months following treat-
ment, were also obtained from four of the eight active patients. 
The sample consisted of 17 female subjects (61%) and 11 male 
subjects (39%). Following biostatistical analysis of the epigenetic 
percentage (%) methylation data, a single CpG site demonstrat-
ing a high level of differential methylation between samples was 
selected for statistical comparison between the three groups at 
that site, as follows: FoxP3 TSDR (49117116), FoxP3 promoter 
(49121204), and TIGIT (114012658) (Figure  8). The median 
CpG site% methylation levels of the FoxP3 TSDR (48 ± 3.6 vs 
59 ± 7.4, P = 0.003) (Figure 8A), FoxP3 promoter (53 ± 11 vs 
72 ± 5.3, P = 0.036) (Figure 8B), and TIGIT (48 ± 3.3 vs 59 ± 3.3, 
P =  0.003) (Figure  8C) CpG sites were significantly lower in 
patients in clinical remission compared with active patients. 
When comparing% CpG site methylation within individual 
patients with active disease at 0 month and resolved disease at 
12 months, a decrease in methylation at the FoxP3 promoter was 
FigUre 7 | Serum cytokines levels (pg/mL) of IL-10, IFNγ, IL-17A, IL-22, and transforming growth factor β (TGF-β) in the three subject groups (active, remission, 
and controls), intracellular levels of IL-10, IFNγ, and IL-17A, and correlation of serum IL-10 and TGF-β levels with T-regulatory cell (Treg) levels. (a) Serum IL-10 
levels. (B) Serum IFNγ levels. (c) Serum IL-17A levels. (D) Serum IL-22 levels. (e) Serum TGF-β levels. (F) Intracellular levels of IL-10, IFNγ, and IL-17A in the 
CD3+CD4+ compartment of T-cells in a patient with active disease at 2 and 6 months after starting immunosuppressive treatment, following 24 h in vitro culture  
with anti-CD3 and anti-CD28 bead stimulation. (g) Bivariate correlation of serum TGF-β (pg/mL) and % Treg frequency, across all subject groups. (h) Bivariate 
correlation of serum IL-10 levels (pg/mL) and % Treg frequency, across all subject groups.
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observed over time whereas the methylation of FoxP3 TSDR and 
TIGIT appeared more stable (Figures 8F–H).
increased levels rOrc Methylation May 
Be a Biomarker of Disease response 
to Treatment
To determine whether there was a difference in methylation at 
epigenetic CpG sites associated with the T-effector transcription 
expression levels (RORγt and T-bet) assessed by flow cytometry in 
this study, bisulfite Amplicon Sequencing using an NGS approach 
was performed using cryopreserved PBMC as described earlier. 
Following biostatistical analysis of the epigenetic percentage (%) 
methylation data, a single CpG site demonstrating a high level of 
differential methylation between samples was selected for statisti-
cal comparison between the three groups at that site, as follows: 
RORC2/RORγT (151798858) and TBX21/T-BET (45810951) 
(Figure 8). The median CpG site% methylation level of RORC2 
was higher in patients in clinical remission (55 ± 3.3 vs 46 ± 3.4, 
P = 0.016) and in control subjects compared with active (55 ± 4.3 
vs 46 ± 3.4, P = 0.014) patients (Figure 8D). Within the active 
patient cohort, higher RORC% CpG methylation levels were 
observed at 12  months compared with 0  month after starting/
changing immunosuppressive treatment (Figures  8I,J). TBX21 
CpG sites had overall low levels of methylation compared with 
the other T-cell-associated epigenetic methylation sites and no 
significant difference in the median% methylation levels was 
found between the three cohorts (Figure 8E).
FigUre 8 | Comparison of % DNA CpG site methylation levels between the three subject groups (a–e) and change in % methylation within individual patients 
diagnosed with active disease at 0 month (commenced on oral treatment) and at 12 months, when disease had resolved (F–J). (a) Between subject % methylation 
at FOXP3 Treg-specific demethylated region (TSDR) (49117116). (B) Between subject % methylation at FOXP3 promoter (49121204). (c) Between subject % 
methylation at TIGIT (114012658). (D) Between subject % methylation at RORC2/RORγT (151798858). (e) Between subject % methylation at TBX21/T-BET 
(45810951). (F) Change in individual % methylation at FOXP3 TSDR (49117116). (g) Change in individual % methylation at FOXP3 promoter (49121204).  
(h) Change in individual % methylation at TIGIT (114012658). (i) Change in individual % methylation at RORC2/RORγT (151798858). (J) Change in individual % 
methylation at TBX21/T-BET (45810951).
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Previous Duration of Oral 
immunosuppressive Treatment is a 
significant Predictor of Methylation 
at FoxP3 TsDr
A bivariate analysis of duration of previous oral treatment 
(months) and CpG methylation at FoxP3 TSDR showed that 
CpG methylation levels at FoxP3 TSDR negatively correlated with 
previous duration of oral immunosuppressive treatment (simple 
linear regression shown in Figure 9). A multivariate linear regres-
sion model of methylation of the FoxP3 TSDR, which included 
the duration of previous oral immunosuppressive treatment (log 
transformed variable) as a predictor, was significant (P = 0.002) 
and explained around 42% of the variance in FoxP3 TSDR. 
Additional predictive variables, including TIGIT+, FoxP3+, IL-10, 
and TGF-β levels, added stepwise to the multiple regression 
model were not significant and were, therefore, removed from 
the final model. Subject age (years) was added to the regression 
model as a co-variate to adjust for its effect on methylation and 
the model remained significant (P = 0.006), explaining around 
41% of the variance in FoxP3 TSDR (Table 4).
TigiT+ Tregs are a sensitive but not 
specific Biomarker of clinical remission in 
sight-Threatening non-infectious Uveitis
A logistic regression model that included TIGIT+ Treg levels 
and subject age (years) as predictors of clinical remission was 
significant [χ2(2) = 18.402, P < 0.001] and a good fit for the data 
[Hosmer and Lemeshow test; χ2(8) = 5.786, P = 0.671] (Table 5). 
It  correctly classified 84% subjects and explained around 45% 
of the variance in clinical remission of sight-threatening non-
infectious uveitis. TIGIT was a significant predictor of clinical 
remission, whereas age was not significant. Peripheral blood 
TIGIT+ Treg levels in the study population of patients with uveitis 
had a sensitivity of 92%, a specificity of 62%, a false positive rate 
TaBle 5 | Summary of logistic regression model of clinical remission.
Odds ratio 95% c.i. P-value
TIGIT+ T-regulatory cell 3.1 1.5, 6.5 0.020*
Age (years) 1.0 0.9, 1.1 0.365
*Significant at the 5% level.
TaBle 4 | Summary of multiple regression model of methylation of FoxP3  
Treg-specific demethylated region.
coefficient P-value
Previous duration of oral immunosuppressive 
treatment (months)
−5.919 0.002**
Age (years) 0.073 0.478
**Significant at the 1% level.
FigUre 9 | Simple linear regression of the duration of the previous oral 
immunosuppression treatment (months) and DNA methylation of FoxP3 
Treg-specific demethylated region (TSDR). Previous duration of oral 
immunosuppressive treatment negatively correlated with DNA methylation at 
FoxP3 TSDR, and this relationship was significant (P = 0.012) when modeled 
with a simple linear regression.
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of 38% and a false negative rate of 8% for detecting clinical remis-
sion (Table S4 in Supplementary Material).
DiscUssiOn
In this study, we investigated the hypothesis that phenotypically 
stable Treg induced by immunosuppressive drugs are associ-
ated with sustained clinical remission of non-infectious uveitis. 
We  did this by performing peripheral blood immunopheno-
typing of large group of patients, who had previously received 
immunosuppressive drug therapy and were in sustained clinical 
remission, and comparing these results with those from patients 
with active uveitis and control subjects. Our data show that the 
frequency of CD4+CD25+FoxP3+ Treg, TIGIT+ Treg, T-bet+ Treg 
and the ratio of CD4+CD25+FoxP3+ Treg to Th1 (T-bet+CD4+) 
T-cells are higher in patients in clinical remission compared with 
patients with active disease. T-bet+FoxP3+ cell levels showed 
significant positive correlation with TIGIT+FoxP3+ cell levels. 
The levels of CD4+FoxP3+TIGIT+ Treg, CD4+CD25+FoxP3+ Treg 
and CD4+FOXP3−TIGIT+ T-cells in each subject sample were 
analyzed as ratios of TIGIT+ Treg to TIGIT+ T-cells (T-cells which 
expressed TIGIT but not FoxP3). These ratios were significantly 
higher in the remission group compared with the active group. 
This suggested that TIGIT expression proportionally increased in 
both the CD4+FoxP3+and the CD4+CD25+FoxP3+ compartment 
(with the highest levels TIGIT expression in the CD25+ subset of 
FoxP3+ cells) of T-cells in the clinical remission group compared 
with the active group, rather than increasing on all T-cells. This 
provides some supporting evidence for the utility of TIGIT as a 
marker of functional Treg, as opposed to being a marker of T-cell 
activation.
We utilized a novel approach of NGS bisulfate sequencing 
targeted toward T-cell genes of interest, to identify whether there 
was an epigenetic immune methylation pattern associated with 
clinical remission in uveitis. In this study, PBMCs from patients 
in clinical remission had lower levels of DNA methylation at CpG 
sites within the FOXP3 TSDR, FOXP3 promoter, and TIGIT loci 
compared with patients with active disease, supporting the higher 
levels of FoxP3 and TIGIT expression detected by flow cytometry 
in these patients. Through in vitro functional studies, we demon-
strate that Treg from patients in clinical remission, a population 
in which there were high levels of Treg and TIGIT expression, 
are effective at suppressing T-cell proliferation. Together, these 
findings suggest that Treg from patients in clinical remission are 
polarized toward Type 1 inflammation and have a stable highly 
suppressive phenotype, characterized by intracellular T-bet and 
extracellular TIGIT expression, respectively, in comparison with 
subjects with active disease.
The cytokine milieu in non-infectious uveitis has been 
previously been investigated by our group and others (42–47). 
In this study, our focus was on investigating serum levels of 
specific cytokines associated with the Treg, Th1 and Th17 subsets 
identified in the flow cytometric analysis. Intracellular cytokine 
levels of IL-10, IFN-γ, and IL-17A were also evaluated in active 
disease at 0 and 6 months after starting therapy, at which time, 
disease had resolved. We found that patients in clinical remission 
had higher serum levels of IL-10 and TGF- β than patients with 
active disease. While control subjects also had higher levels of 
IL-10 than active patients, the higher serum TGF- β differentiated 
remission patients from controls and were perhaps related to high 
levels of Treg with suppressive function in this group. Tregs levels 
positively correlated with serum IL-10 and TGF- β levels, suggest-
ing that Tregs may directly or indirectly influence the systemic 
cytokine milieu. Furthermore, increased intracellular expression 
of IL-10 by T-cells from active disease was increased 6 months 
after starting treatment, which corresponded with clinical resolu-
tion of disease.
Subjects’ levels of Th1 and Th17 were evaluated by flow 
cytometric detection of their respective transcription factors, 
T-bet and RORγt, along with the corresponding serum cytokine 
levels of IFN-γ, IL-17, and IL-22 from peripheral blood samples. 
Upregulated T-bet expression in association with significantly 
increased IFN-γ levels has been previously demonstrated in 
patients with active uveitis secondary to Vogt–Koyanagi–Harada 
(VKH) syndrome, a bilateral chronic granulomatous panuveitis, 
which tends to be sight-threatening (48). Th17  cells have also 
been shown to be involved in ocular inflammation (49) and, 
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more recently, B27+ anterior uveitis (50). Paradoxical expression 
of effector CD4 T-cell transcription factors, such as T-bet and 
RORγt, by Treg has, however, been suggested to enhance Treg 
suppressive capacity in murine models of inflammation (51–54). 
These models demonstrate that intestinal RORγt+FoxP3+ Treg 
induced in vivo by the local microbiota display a stable suppressive 
phenotype and exist in dynamic balance with pathogenic Th17 
(53, 55). The local microenvironment, for example, the cytokine 
milieu and/or the microbiome, have been shown to regulate the 
Treg/Th17 balance and influence cell plasticity; disruption of this 
balance may lead to the development of inflammatory disease 
(54–57). Furthermore, during Type 1 inflammatory responses, 
Treg may upregulate T-bet in response to IFN-γ production (51). 
These T-bet+ Treg have been observed to be phenotypically stable 
and selectively suppressive of Th1 (52). However, it is noted that 
other studies have demonstrated that T-bet expression is not 
required for Treg to suppress inflammation, in the context of CNS 
inflammation and colitis (58).
In this study, we show that in clinical remission and control 
groups, the levels of T-bet+ Treg and ratios of Treg to Th1 are 
higher and serum levels of IFN-γ levels are lower compared with 
active uveitis patients. We also found that T-bet+ Th1 levels in 
uveitis patients were overall lower in clinical remission compared 
with active and control subjects. Disease resolution in active 
patients over the course of 12 months appeared to be associated 
with an increase in levels of Treg and a decrease in levels of Th1. 
Intracellular expression levels of IFN-γ by CD4+ T-cells were 
also decreased at 6  months after starting treatment. However, 
RORγt+ Th17 and RORγt+ Treg levels did not significantly differ 
between the three subject groups. Tregs are thought to regulate 
the expression of IL-22, a Th17 cytokine which facilitates inflam-
matory cell infiltration in uveitis (59, 60). Although the ratio of 
Treg to Th17 was not significantly greater in clinical remission, it 
was noted that serum IL-17A and IL-22 levels were significantly 
lower in the patients in clinical remission, compared with active 
and control subjects. RORγt+ Treg levels were increased in all 
four active patients at 12 months compared with baseline, as the 
disease clinically resolved. However, unlike Th1 cytokine levels, 
Th17 cytokine levels did not appear to consistently decrease when 
disease resolved in active patients. Three out of four active patients 
had increased serum levels of IL-17A at 12 months after starting 
treatment, compared with baseline. Intracellular expression levels 
of IL-17A of by CD4+ T-cells in active disease also increased at 
6  months after starting treatment. Our results show that Th17 
express FoxP3+ during disease resolution, in response to immu-
nosuppressive treatment, but suggest that Th17-mediated inflam-
mation is not driving inflammation and that FoxP3+RORγt+ Tregs 
are not significantly associated with clinical remission.
It was further investigated whether clinical remission in 
non-infectious sight-threatening uveitis could be modeled by a 
linear relationship with predictive immunological variables, after 
adjusting for co-variates in the model. Multiple regression analy-
sis showed that the duration of previous oral immunosuppres-
sive treatment was the strongest predictor of hypomethylation 
at the FoxP3 TSDR (with the simple linear regression analysis 
demonstrating an observable hypomethylation effect of oral 
immunosuppression at the FoxP3 TSDR over several months of 
treatment). Hypomethylation at the FoxP3 TSDR has been shown 
to be important for Treg suppressive function and phenotypic 
stability and was significantly associated with clinical remission 
in our analysis. The association between previous duration of oral 
immunosuppression and methylation at FoxP3 TSDR remained 
significant after adjusting for subject age. This suggests that the 
duration of oral immunosuppression is an important factor in 
determining the phenotypic stability of Treg and supports the role 
of immunosuppressive drug induced Treg in the maintenance of 
clinical remission. Logistic regression showed that peripheral 
blood TIGIT levels, but not subject age, were a significant pre-
dictor of clinical remission in sight-threatening non-infectious 
uveitis. TIGIT+ Treg levels had high sensitivity (92%) but low 
specificity (62%) for clinical remission. This infers a high false 
positive rate for using TIGIT+ Treg as a predictor of clinical remis-
sion, that is, a patient could test positive for disease remission 
when they actually have subclinical active disease. TIGIT+ Treg 
levels detected by flow cytometry explained almost half of the 
variance observed in this model of clinical remission. However, 
many other factors not accounted for in this analysis, for example, 
posttranslational protein modifications and other immune mark-
ers such as chemokines, could also influence clinical remission.
Previous studies have compared Treg levels between active 
uveitis, inactive uveitis and/or healthy control subjects but there 
has been variation in subject groups and clinical immunopheno-
typing. A study from Chen et al. included 49 patients with VKH 
syndrome with uveitis and without uveitis, and showed a decreased 
percentage of CD4+CD25high T-cells, a decreased frequency of 
Foxp3+ expression in CD4+CD25high T-cells and reduced func-
tionality of CD4+CD25high “Treg” in patients with active uveitis 
(61). Yeh et al. also demonstrated that patients with active uveitis 
(n = 8) have lower percentages of CD4+FoxP3+  lymphocytes than 
patients with inactive disease (n = 12) (13). In contrast to this 
study, several patients in their series demonstrated evidence of 
systemic autoimmune disease, such as sarcoidosis and multiple 
sclerosis, which are, of themselves, associated with abnormal Treg 
populations or deficits in Treg suppressive function. Another study 
compared Treg levels in active and inactive uveitis patients and 
found that patients in remission on treatment (n = 25) had sig-
nificantly increased levels of CD4+CD25+FoxP3+ Treg compared 
with active patients on treatment (n = 6) (12). However, over half 
of the patients (53%) recruited to their study had a diagnosis of 
anterior uveitis, which is not usually sight-threatening and does 
not require systemic immunosuppression.
Regarding the comparison of Treg levels in active patients with 
control subjects, the results from the literature are mixed. Two 
of aforementioned studies show a higher level of Treg in control 
subjects compared with uveitis patients (12, 61); however, this 
could be due to the inclusion of patients with systemic disease in 
the uveitis groups. By contrast, Yeh et al. comment that they have 
previously observed that the percentages of CD4+FoxP3+ lympho-
cytes do not differ between patients with uveitis and control sub-
jects (unpublished data) (13). Molins et al. compared Treg levels 
and cytokine production in 21 patients with active non-infectious 
uveitis with 18 controls (18). They found that PBMCs from uveitis 
patients produced lower levels of IL-10 than those from controls 
but no differences were observed in Treg levels. TGF-β levels 
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were not measured and functional assays were not performed 
in this study. Recently, Zhuang et al. compared 20 patients with 
active B27+ anterior uveitis with healthy controls and observed an 
increase in CD4+IL-17+ T cells, a decrease of CD4+CD25+Foxp3+ 
Treg and a higher ratio of Th17/Treg in peripheral blood of 
patients compared with controls (50). The authors conclude that 
the imbalance of Th17 and Treg cells may play a vital role in the 
pathogenesis of B27+ anterior uveitis. Of note, patients with B27+ 
uveitis and anterior uveitis were excluded from this study due to 
the typically non-sight-threatening anterior anatomic localization 
of inflammation and systemic disease associations.
There has been interest in glucocorticoid-resistant Th17  cells 
which are refractory to Treg mediated suppression (62, 63), and 
these have been previously investigated in sight-threatening uveitis 
(64). Furthermore, a subset of “non-classic” Th17-derived Th1 have 
been described, which are demethylated at RORC, and are thought 
to play a pivotal role in the establishment and persistence of 
inflammatory disease (65). These non-classic Th1 express CD161, 
a marker of steroid-resistant human Th17, induced by RORC 
(66). In the clinical setting, however, most cases of uveitis show 
a good clinical response to high dose corticosteroids. Second-line 
immunosuppressive drugs are usually prescribed because the dose 
of corticosteroids required to suppress disease activity is very high 
and disease recurs on tapering the dose, rather than because the 
disease is refractory to corticosteroids. Only one patient in this 
study received biological therapy (Adalimumab), as the rest were 
clinically responsive to corticosteroids, with or without addition of 
conventional steroid-sparing agents. Twenty percent of the clinical 
remission group received previous therapy with cyclosporine, which 
has been shown to selectively attenuate steroid-resistant Th17 and 
to be efficacious in the treatment of steroid-refractory disease (67, 
68). It is of note, in this study, that the clinical remission and control 
groups had significantly higher levels of RORC CpG methylation 
than the active group. Furthermore, within the active patient 
cohort, higher RORC% CpG methylation levels were observed at 
12 months after starting/changing immunosuppressive treatment, 
when disease had resolved. RORC CpG hypermethylation could be 
a biomarker of clinical responsiveness to corticosteroid treatment; 
however, this requires further investigation.
The findings of this study are consistent with previous studies 
in uveitis demonstrating that Treg levels are higher and more 
functional in patients with inactive disease, compared with both 
patients with active and control subjects. We have previously 
observed that in ocular Behçet’s disease, peripheral blood Treg 
levels are increased by 3  months’ treatment with the immu-
nomodulating therapy, pegylated interferon-α (pegIFNα), and 
that the increased levels of Tregs are still detectable at 12 months, 
6  months after cessation of therapy (16). However, the expres-
sion of the co-inhibitory molecule TIGIT by Treg from patients 
in sustained clinical remission of disease, who are no longer 
on therapy, has not been previously investigated in uveitis. It is 
known that stable FoxP3 expression is ensured, at least partly, 
by DNA demethylation at the FOXP3 TSDR and that this infers 
commitment to the Treg lineage (28–31). In a genome-wide meth-
ylation analysis of nTregs from healthy individuals, it was found 
that hypomethylation at the TIGIT locus was one of the most 
significantly differentially methylated regions that distinguished 
naïve T-cells and nTreg; that it was not altered by activation and 
is required for FoxP3 binding (36). Other studies have demon-
strated a key role for TIGIT in Treg-mediated suppression of 
Th1 and Th17 subsets (35, 37) and that TIGIT signaling in Treg 
directs their immunoregulatory phenotype in chronic disease 
settings (69). Our data show that hypomethylation at FOXP3 
TSDR, FOXP3 promoter, and TIGIT CpG sites and higher levels 
of TIGIT+ Tregs are associated with clinical remission, and may 
have value in determining remission, of relapsing and remitting 
sight-threatening non-infectious uveitis.
Our study addressed a need to define and investigate peripheral 
biomarkers for sustained clinical and biological disease remission 
in sight-threatening non-infectious uveitis. The total number of 
subjects recruited to this study (n =  60) represents one of the 
largest sample sizes of published clinical immunology studies of 
sight-threatening non-infectious uveitis. To improve the specific-
ity of this study toward detecting peripheral blood biomarkers 
associated with ocular inflammation, we excluded patients with 
known systemic diagnoses, for example, sarcoidosis or Behçet’s 
disease, and any other identifiable systemic inflammation. We 
were rigorous in our clinical phenotyping of the recruited subjects 
and undertook a comprehensive immunophenotypic analysis of 
CD4+ T-cells derived from these groups, including functional and 
epigenetic methylation studies, which has not been previously 
performed in uveitis patients. Our group has previously analyzed 
aqueous humor samples from the eyes of patients with uveitis 
(47). However, the procedure of direct intraocular sampling 
carries risks of introducing infection, triggering or exacerbating 
inflammation and causing retinal detachment to the eye being 
sampled. Even when it is deemed clinically necessary, sequential/
repeated intraocular sampling should be avoided. Therefore, 
T-cell immunophenotyping by flow cytometry was performed 
on freshly isolated subject PBMCs (within 4 h of venepuncture), 
but additional intraocular sampling was not undertaken as part 
of this study. The 37 patients in clinical remission recruited to the 
study demonstrated a good clinical ocular response to immuno-
suppressive therapy given systemically, supporting the fact that 
systemic Treg and their associated microenvironment influence 
ocular immunity and that peripheral blood biomarkers have 
utility in monitoring ocular disease. Phenotypic analysis of Treg, 
Th1, and Th17 subtypes was based on “master transcription fac-
tor” expression, with prospective intracellular cytokine analysis 
only in selected subjects with active disease, followed up over a 
12-month period. An in-depth analysis of intracellular cytokine 
production and methylation at signature cytokine loci could be 
considered for a future study. The number of Treg functional 
assays that were performed as part of this study was limited by the 
remaining PBMC numbers after the immunophenotypic analysis, 
rendering firm conclusions from these results difficult. The assay 
findings were in keeping with those from previous studies, which 
have demonstrated that in the inflammatory setting of autoim-
mune disease, Treg have reduced suppressive function (11, 70). 
However, they could be confirmed as part of a further study.
The clinical utility of TIGIT+ Treg as a single biomarker for 
remission is limited by its potentially high false positive rate 
in this regard. It is possible that the calculated test sensitivity, 
specificity, false positive and negative rates were skewed by the 
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overweighting of the sample toward remission patients rather 
than active patients. TIGIT levels explained almost half of the 
variance observed in the model of clinical remission, but there 
may be other clinically relevant factors, not accounted for in the 
model, which were also influencing clinical remission. These 
would need to be further investigated to develop better models 
for predicting clinical remission for individual patients, which 
could augment standard clinical assessment of patients. However, 
our results suggest that low levels of TIGIT may be a biomarker 
for increased risk of disease relapse in sight-threatening non-
infectious uveitis. This could help to inform clinical management 
decisions, by indicating whether immunosuppressive drugs have 
induced functionally suppressive Treg.
In summary, our data show that CD4+ T-cells in chronic 
relapsing, remitting sight-threatening non-infectious uveitis 
deviate toward the Th1 type and that Treg with upregulated levels 
of T-bet and TIGIT expression are associated with disease remis-
sion. These data provide supporting evidence that Tregs are part 
of the mechanism of clinical remission in non-infectious uveitis, 
which has been previously demonstrated in EAU model studies 
only (7–9). We suggest that the overall lower T-bet expression and 
IFN-γ levels detected in patients who achieve sustained clinical 
remission are related to potent suppression of Type 1 inflamma-
tion by phenotypically stable Treg induced by systemic immuno-
suppressive therapy. This is an important finding because a recent 
study in mice has shown that Treg expressing T-bet have a stable 
and functional phenotype, which potentiates suppression of 
Th1 autoimmunity (52), but it has not yet been demonstrated in 
clinical studies. Our results are also consistent with evidence from 
EAU that relapsing, remitting uveitic disease is closely associated 
with a Th1-like phenotype whereas monophasic inflammation is 
associated with a Th17-like phenotype (71).
Finally, these data are relevant to the recent interest in quan-
titative identification and isolation of viable, functional Treg for 
downstream clinical purposes, which include their generation 
ex vivo for immunomodulating therapies (72, 73). The results of 
this study provide evidence that TIGIT has utility as a marker of 
functional Treg for these therapies.
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FigUre s1 | Bisulfite amplicon epigenetic CpG methylation target sites for 
FOXP3 TSDR, FOXP3 promoter, TBX21, RORC2, and TIGIT loci.
TaBle s1 | Kruskal–Wallis post-hoc test pairwise comparisons of immunological 
markers across the three subject groups.
TaBle s2 | Primer sequences used in the Fluidigm assay for DNA methylation 
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Fluidigm assay for DNA methylation analysis.
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